Project Grant R01CA307511
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $766K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
- The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $168,000 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 1, 2025, with completion scheduled for June 30, 2027. The award funds research to examine risk factors and develop predictive models for multiple recurrences of non-muscle invasive bladder cancer (NMIBC). The research leverages existing demographic, lifestyle,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a $2.1 million Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective September 1, 2025, through August 31, 2030. This P01 (Program Project) grant funds a multi-institutional research initiative focused on elucidating the mechanisms of bladder cancer development and identifying therapeutic vulnerabilities to preventive and interventive...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 project grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025 and concluding August 31, 2027. This grant funds research investigating P300/CBP (lysine acetyltransferases) as novel therapeutic targets in clear cell renal cell carcinoma (ccRCC). The research will examine the therapeutic potential of targeting P300/CBP through pharmacological...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $581,381 to Sloan-Kettering Institute for Cancer Research on June 5, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the role of microhomology-mediated end-joining (MMEJ) in DNA damage repair and its implications for cancer drug resistance. The five-year research initiative (concluding May 31, 2030) will produce scientific research and experimental findings...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded $125,619 to the Stowers Institute for Medical Research under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This Project Grant supports research into centromere biology and chromosome segregation mechanisms that contribute to genomic instability—a hallmark of cancer development. The primary deliverables include experimental research characterizing how natural...
- Federal Grant Award Summary Health Research, Inc. at Roswell Park received a $639,379 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) beginning May 1, 2026, with a completion date of April 30, 2031. The award funds research to develop and validate neuroendocrine bladder carcinoma (NEBC) models for translational research, addressing the critical need to understand NEBC pathogenesis and overcome chemotherapy resistance. The project...
- Federal Project Grant Award Summary The University of Pittsburgh received a $412,856 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2028. This award funds research investigating the role of cell cycle plasticity in bladder cancer growth and progression. The research will generate a systematic catalog of cell cycle heterogeneity across 661 bladder tumors using single-cell spatial proteomics...